Foghorn Therapeutics Inc. (NASDAQ: FHTX)
$6.60
+0.3500 ( +5.60% ) 182.2K
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
Market Data
Open
$6.60
Previous close
$6.25
Volume
182.2K
Market cap
$369.04M
Day range
$6.17 - $6.98
52 week range
$2.70 - $9.97
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 73 | Jun 03, 2024 |
4 | Insider transactions | 1 | May 24, 2024 |
3 | Insider transactions | 1 | May 24, 2024 |
8-k | 8K-related | 72 | May 23, 2024 |
8-k | 8K-related | 17 | May 22, 2024 |
8-k | 8K-related | 72 | May 20, 2024 |
8-k | 8K-related | 14 | May 06, 2024 |
10-q | Quarterly Reports | 55 | May 06, 2024 |
8-k | 8K-related | 58 | May 06, 2024 |
ars | Annual reports | 1 | May 03, 2024 |